Albany, NY -- (SBWire) -- 04/19/2019 --Malaria is a mosquito-borne infectious disease affecting humans and animals caused by parasitic protozoan belonging to the plasmodium family. Malaria is typically transmitted from human to human through the bite of an infected Anopheles (female) mosquito. Symptoms of malaria include fever, headache, fatigue, muscle pain, diarrhea, anemia, and vomiting. Severe malaria can cause yellow skin, seizures, coma, or death. Cerebral malaria is a form of severe malaria. Cerebral malaria has high mortality rate and can cause various complications in the neurology. Cerebral malaria causes CNS manifestations which includes any degree of impaired consciousness, abnormal neurological signs, delirium, and focal and generalized convulsions. Causes of neurological manifestations in cerebral malaria are due to high-grade fever, anti-malarial drugs, hypoglycemia, hyponatremia, and severe anemia. Patients of cerebral malaria exhibit symptoms such as nystagmus, seizures, or fall into coma. Artemisinin derivatives are used for the treatment of ce­rebral malaria in children.

The global Cerebral Malaria Therapeutics Market has been segmented based on drug class, distribution channel, and region. In terms of drug class, the market has been categorized into anti-malarial, tetracycline antibiotics, anti-rheumatics, anti-arrhythmics, and analgesics & pain relievers. The anti-malarial segment holds the largest share of the cerebral malaria therapeutics market due to increasing incidence of malaria globally. The tetracycline antibodies segment is likely to witness high growth in the next few years driven by effective treatment/killing of the parasite causing malaria. Based on distribution channel, the market has been classified into hospital pharmacies, retail pharmacies, drug store, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the market due to easy access for outpatient department (OPD) patients to buy medicines. Online pharmacies are likely to witness lucrative growth during the forecast period due to increasing online purchase by patients and various discounts offered by online stores.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20519

Geographically, the cerebral malari­a therapeutics market has been segmented into five major regions: North America (U.S. and Canada), Europe (Germany, France, U.K., etc.), Asia Pacific (Australia, China, Japan, India, etc.), Latin America (Brazil, Mexico, etc.), and Middle East &Africa (GCC Countries, South Africa, etc.). North America is the leading market for cerebral malaria therapeutics drugs in terms of revenue, followed by Europe. The U.S. holds the largest share of the market in the region. Asia Pacific and Latin America are emerging markets, which are expected to witness strong growth during the forecast period from 2016 to 2014. Strong growth in these regions is attributed to increasing incidence of malaria, rising health care industries, and increase in government investment to develop health care infrastructure. The cerebral malaria therapeutics market in countries such as China, India, and Brazil is projected to expand at high growth rate during the forecast period due to increase in awareness among the population about malaria disease and its treatment.

Other factors that drive the cerebral malaria therapeutics market are rising prevalence of cerebral malaria, increasing novel drug treatment, convenience of direct purchase, affordability of drugs, high adoption and acceptance in developing markets, and innovations and developments in drugs. The market is also experiencing certain restraints such as stiff competition among existing players, high possibilities of substance abuse and addiction, complications and severity involved in taking wrong medications due to misdiagnosis or incorrect self-diagnosis, and lack of awareness among the rural population in developing and underdeveloped economies.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=20519

Major players operating in the cerebral malaria therapeutics market include Quepharma, Cipla, Inc., Ipca Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Guilin Pharmaceutical (Shanghai) Co., Ltd., Novartis AG, Mylan Labs, Ajanta Pharma, Sanofi, and Astra Zeneca plc.